The effects of booster vaccination of hepatitis B vaccine on anti-HBs negative children 11-15 years after primary vaccination

被引:12
作者
Yao, Jun [1 ]
Ren, Jingjing [2 ]
Shen, Lingzhi [3 ]
Chen, Yongdi [1 ]
Liang, Xiaofeng [4 ]
Cui, Fuqiang [4 ]
Li, Qian [1 ]
Jiang, Zhenggang [1 ]
Wang, Fuzhen [4 ]
机构
[1] Zhejiang Univ, Zhejiang Ctr Dis Control & Prevent, Affiliated Hosp 1, Dept Immune Prevent,Sch Med, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Dept Family Med, Affiliated Hosp 1, Sch Med, Hangzhou 310027, Peoples R China
[3] Ningbo Univ, Dept Epidemiol & Stat, Sch Med, Ningbo 315211, Zhejiang, Peoples R China
[4] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China
来源
HUMAN VACCINES | 2011年 / 7卷 / 10期
关键词
anti-HBs; hepatitis B vaccine made by recombinant deoxyribonucleic acid (DNA) techniques in Chinese hamster ovary (CHO) cells; HepB (CHO); booster vaccination; effect; LONG-TERM EFFICACY; VIRUS INFECTION; DISEASE BURDEN; ADOLESCENTS; PROTECTION; IMMUNOGENICITY; IMMUNIZATION; IMMUNITY; INFANTS;
D O I
10.4161/hv.7.10.15990
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The twin aims of this study were to investigate the changes in anti-HBs IgG levels after booster vaccinations and to compare the effects of different vaccine doses in children aged 11-15 years who were both negative for HBsAg and had an Anti-HBs <10.0 mIU/mL after primary vaccination. Children who were born between 1993 and 1998 and who had completed their Hepatitis B vaccination program in infancy were randomly recruited to the study. The participants were divided into three groups according to their anti-HBs IgG levels: group I had a level <0.1 mIU/mL; group II 0.1-<1.0 mIU/mL and group III 1.0-<10.0 mIU/mL. The booster vaccination program comprised three (20 mu g) doses of HepB (CHO) vaccine administered at zero, one and six months after they are join this program: anti-HBs levels were measured one month after the first and third vaccinations. Among 448 HBsAg-negative infants, anti-HBs seroconversion rates (defined as an anti-HBs >= 10 mIU/mL) after the first and third vaccinations were 85.5% and 98.6% respectively-these observed differences were statistically significant (chi(2) [1d of] = 50.11, p < 0.05). Seroconversion rates and GMTs after the first and third doses were significantly lower for group I children than the other two groups (p < 0.05). Compared, the OR of being negative (anti-HBs < 10 mIU/ml) in group I after the first and the third dose were 7.66 (95% CI: 4.35-13.47, p < 0.05) and 20.48 (95% CI: 2.36-177.67, p < 0.05). So the anti-HBs titer levels decay to 10 mIU/ml in 11-15 years of age children completed HepB Basic immunization, which need for booster immunization. The effect is better for those children with a relatively higher antibody titer before booster, and the effect of three doses booster is best.
引用
收藏
页码:1055 / 1059
页数:5
相关论文
共 30 条
  • [1] [Anonymous], Hepatitis B vaccines
  • [2] Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth - A 75-year follow-up study
    Bialek, Stephanie R.
    Bower, William A.
    Novak, Ryan
    Helgenberger, Louisa
    Auerbach, Steven B.
    Williams, Ian T.
    Bell, Beth P.
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (10) : 881 - 885
  • [3] Acute and chronic hepatitis: Working Group Report of the Second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition
    Chang, MH
    Hadzic, D
    Rouassant, SH
    Jonas, M
    Kohn, IJ
    Negro, F
    Roberts, E
    Sibal, A
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2004, 39 : S584 - S588
  • [4] Improved anamnestic response among adolescents boosted with a higher dose of the hepatitis B vaccine
    Chaves, Sandra S.
    Groeger, Justina
    Helgenberger, Louisa
    Auerbach, Steven B.
    Bialek, Stephanie R.
    Hu, Dale J.
    Drobeniuc, Jan
    [J]. VACCINE, 2010, 28 (16) : 2860 - 2864
  • [5] 12-YEAR FOLLOW-UP-STUDY OF HEPATITIS-B IMMUNIZATION OF SENEGALESE INFANTS
    COURSAGET, P
    LEBOULLEUX, D
    SOUMARE, M
    LECANN, P
    YVONNET, B
    CHIRON, JP
    COLLSECK, AM
    DIOPMAR, I
    [J]. JOURNAL OF HEPATOLOGY, 1994, 21 (02) : 250 - 254
  • [6] Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences
    Ganem, D
    Prince, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1118 - 1129
  • [7] A mathematical model to estimate global hepatitis B disease burden and vaccination impact
    Goldstein, ST
    Zhou, FJ
    Hadler, SC
    Bell, BP
    Mast, EE
    Margolis, HS
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2005, 34 (06) : 1329 - 1339
  • [8] Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
    Hsu, HY
    Chang, MH
    Liaw, SH
    Ni, YH
    Chen, HL
    [J]. HEPATOLOGY, 1999, 30 (05) : 1312 - 1317
  • [9] What level of hepatitis B antibody is protective?
    Jack, AD
    Hall, AJ
    Maine, N
    Mendy, M
    Whittle, HC
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (02) : 489 - 492
  • [10] Long-term efficacy of immunization against hepatitis B virus in infants at high-risk analyzed by polymerase chain reaction
    Kato, H
    Nakata, K
    Hamasaki, K
    Hida, D
    Ishikawa, H
    Aritomi, T
    Nakao, K
    Kato, Y
    Yano, M
    Eguchi, K
    [J]. VACCINE, 1999, 18 (7-8) : 581 - 587